Industry / innovation partners

ALS Biomarkers Are Entering the Approval Fight

The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself

Oral GLP-1 drugs could widen access, but high prices may do the opposite

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Boehringer Ingelheim is adding a third target to obesity treatment.

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.

The Cyclospora Test Was Wrong. Public Trust Cannot Be

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

China Just Put a Bispecific ADC Into Esophageal Cancer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
